Last week, Amgen (Onyx) announced negative news from its FOCUS clinical trial of multiple myeloma drug Kyprolis. Let’s put this into perspective. Continue reading
Last week, Amgen (Onyx) announced negative news from its FOCUS clinical trial of multiple myeloma drug Kyprolis. Let’s put this into perspective. Continue reading